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Abstract
The 1986 accident at the Chernobyl nuclear power plant remains the most serious nuclear accident in history, and excess
thyroid cancers, particularly among those exposed to releases of iodine-131 remain the best-documented sequelae. Failure
to take dose-measurement error into account can lead to bias in assessments of dose-response slope. Although risks in the
Ukrainian-US thyroid screening study have been previously evaluated, errors in dose assessments have not been addressed
hitherto. Dose-response patterns were examined in a thyroid screening prevalence cohort of 13,127 persons aged ,18 at
the time of the accident who were resident in the most radioactively contaminated regions of Ukraine. We extended earlier
analyses in this cohort by adjusting for dose error in the recently developed TD-10 dosimetry. Three methods of statistical
correction, via two types of regression calibration, and Monte Carlo maximum-likelihood, were applied to the doses that can
be derived from the ratio of thyroid activity to thyroid mass. The two components that make up this ratio have different
types of error, Berkson error for thyroid mass and classical error for thyroid activity. The first regression-calibration method
yielded estimates of excess odds ratio of 5.78 Gy21 (95% CI 1.92, 27.04), about 7% higher than estimates unadjusted for
dose error. The second regression-calibration method gave an excess odds ratio of 4.78 Gy21 (95% CI 1.64, 19.69), about
11% lower than unadjusted analysis. The Monte Carlo maximum-likelihood method produced an excess odds ratio of 4.93
Gy21 (95% CI 1.67, 19.90), about 8% lower than unadjusted analysis. There are borderline-significant (p = 0.101–0.112)
indications of downward curvature in the dose response, allowing for which nearly doubled the low-dose linear coefficient.
In conclusion, dose-error adjustment has comparatively modest effects on regression parameters, a consequence of the
relatively small errors, of a mixture of Berkson and classical form, associated with thyroid dose assessment.
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Introduction
The accident at the Chernobyl nuclear power plant remains
the most serious nuclear accident in history. Thyroid cancer was
the first cancer to be elevated among the exposed residents in
Ukraine and Belarus, within 5 years of the accident, and the
excess is particularly marked among those exposed in childhood
[1–4]. The thyroid cancer excess is thought to be largely the
result of release of radioactive iodine-131 (131I) from the
Chernobyl reactor.
In collaboration with the Institute of Endocrinology and
Metabolism, Kyiv, Ukraine and Columbia University, the U.S.
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National Cancer Institute initiated a cohort screening study of
children and adolescents exposed to Chernobyl fallout in Ukraine
to better understand the long-term health effects of exposure to
radioactive iodines [5]. Unlike many other studies of thyroid
cancer in relation to environmental exposure [6,7], this cohort
incorporates detailed thyroid activity measurements, and mass
estimates derived from a similar external Ukrainian sample,
crucial to estimates of dose. There have been a number of
analyses of this cohort [3,8], which document the significant
increased risk of thyroid cancer in relation to 131I thyroid dose. A
major source of uncertainty in estimation of low dose risk
concerns the extrapolation of risks at high dose and high dose-
rates to those at low doses and low dose-rates. Crucial to the
resolution of this area of uncertainty is consideration of both
systematic and random dosimetric errors in analyses of the
Chernobyl-exposed and other exposed groups. The problem of
allowing for errors in dose assessments when estimating dose-
response relationships has recently been the subject of much
research [9]. It is well recognized that measurement error can
alter substantially the shape of this relationship and hence the
derived study risk estimates [9]. Typically errors are assumed to
be of one of two types, classical or Berkson. Classical errors, in
which the measured doses are assumed to be distributed with
(independent) error around the true dose, generally result in a
downward bias of the dose-response parameter [9]. Berkson
errors, in which the true dose is randomly distributed around a
measured dose estimate, do not result in biased estimates of the
dose-response parameter for linear models, although for non-
linear models that is not the case [9]. Classical dose errors are
generally thought to characterize the errors in dose estimates in
the Japanese atomic bomb survivors [10], whereas Berkson errors
are thought to dominate the dose uncertainties in certain medical
studies [11]. In practice, errors associated with measurement of
doses are a mixture of classical and Berkson errors and each type
of dose error can include both a shared component, common to
all individuals within a group, and an unshared part, unique to
an individual within a cohort [12]. Kukush et al. [13] developed
a novel methodology for assessing dose error in a (simulated)
Chernobyl-exposed cohort, incorporating both Berkson errors
(relating to thyroid mass estimates), and classical errors (relating
to thyroid activity assessments). When dose errors are modest, a
commonly used method of dealing with dose error is to replace
the dose estimate in any regression with the expected true dose
given the measured dose estimate, a process termed regression
calibration [9]. When dose uncertainties are more substantial
full-likelihood methods may be indicated, in particular Monte
Carlo maximum likelihood integration (MCML) [12,14], and
Bayesian Markov Chain Monte Carlo (MCMC) [10].
The dose-response for prevalent thyroid cancers in the
Ukrainian-US screening cohort was previously analyzed [3]
using the original (TD-02) individual dose estimates, while the
dose response for incident thyroid cancer cases was analyzed [8]
using a modified version of TD-02, in which adjustments were
made to reflect an increased understanding of thyroid mass
measurements in the cohort. A further review has resulted in a
new set of thyroid dose estimates, referred to as TD-10 [15]. In
this paper we assess the impact on thyroid cancer risk of a
number of methods of adjustment for the effects of dose
uncertainty, in particular regression-calibration and MCML
procedures. Most analyses use the TD-10 dosimetry; we also
briefly compare our results with those of Tronko et al. based on
the TD-02 doses [3].
Data and Methods
Ethics Statement
The data were hosted at three collaborating institutions:
Institute of Endocrinology and Metabolism, Kyiv, Ukraine,
Columbia University/University of California San Francisco
(UCSF), and the National Cancer Institute (NCI). All subjects
signed an informed consent form, and the study was reviewed and
approved by the institutional review boards of the participating
institutions in both Ukraine and the United States. The data were
de-identified before transfer to the United States participating
institutions. The key to the data exists in Ukraine, but US
researchers did not have access to it at any point. Anonymized
data can be provided upon request with conditions agreeable to
the three parties (Institute of Endocrinology and Metabolism,
Kyiv, Ukraine, Columbia University/UCSF, NCI). At NCI, it has
to be formalized through the Technical Transfer Center.
Study data
The Ukrainian-US prevalence cohort includes 13,127 individ-
uals (44% of the 29,919 potentially available subjects originally
selected for the study [3]) who were less than 18 years old on April
26 1986. All cohort members were required to have had at least
one direct measurement of thyroid radioactivity between April 30
and June 30, 1986 and to have resided at the time of screening
(which was highly correlated with residence at the time of the
accident) in the northern areas of Ukraine (Kyiv city and oblast,
Zhytomyr, and Chernihiv oblasts), which were the most radioac-
tively contaminated territories in Ukraine as a result of the
Chernobyl accident. Thyroid activity measurements were made by
means of several types of gamma-counters held against the neck,
from which was derived (via subtraction of the background
radiation count and other variables) the 131I activity in the thyroid
gland. For 6 subjects a current (TD-10: see below) thyroid dose
could not be estimated; they were excluded from the main analysis
cohort for all analyses based on TD-10 doses, but were included
for analyses based on TD-02 doses. There were a total of 45
thyroid cancer cases, exactly as in the data of Tronko et al. [3].
Revised dose estimates
The first estimates of individual thyroid doses for all members of
the Ukrainian-US cohort were obtained in 2002 (TD-02). Along
with a description of the corresponding thyroid dose reconstruc-
tion system, the first dose estimates were published by Likhtarev
et al. [16]. For the second (TD-10) set of thyroid dose estimates
[15,17] the following improvements were carried out:
N A second round of interviews for all cohort members was
conducted so that detailed information on personal history
(relocation from the contaminated territory and consumption
of contaminated foods) could be clarified.
N Parameters of the dosimetry model were substantially
improved. They includes estimates of 131I ground deposition
on the Ukrainian territory using a new mesoscale model of
atmospheric transport of the radioactive materials released
during the Chernobyl accident; site-specific values of model
parameters derived from the available data on radionuclide
transport in the environment that were published after the
Chernobyl accident; evaluation of the contribution of the
incorporated radiocesiums to the signal read by the detectors.
N Oblast-specific thyroid mass estimates were derived using
measurements of thyroid volume performed during the 1990s
by the Sasakawa Memorial Health Foundation among
children and adolescents of Kyiv and Zhytomyr oblasts [18].
Thyroid Cancer Exposure Assessment Uncertainty
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The component of the reconstruction model dealing with the
input data resulting from direct individual measurement of thyroid
activity (Qmesi ) and thyroid mass (M
mes
i ) has not been revised; this
revision is now underway [19,20].
Dose error model
The probabilistic models of thyroid mass and thyroid activity
are outlined in Appendix S1. These are applied to the current
(TD-10) set of dose estimates. The thyroid mass at the time of the
Chernobyl accident was estimated via population-average mea-
surements performed on children aged 5 to 16, taken within a few
years of the accident in Kyiv and Zhytomyr oblasts by the
Sasakawa Health Memorial foundation [18], supplemented with
autopsy measurements conducted on newborns and infants [19];
data for missing ages were obtained via interpolation or
extrapolation. The currently available estimates of thyroid mass
are those used by Likhtarov et al. [15]. The true values of the
thyroid mass are determined according to a Berkson measurement
error model. For the first regression-calibration method, adapted
from Kukush et al. [13], Supporting Information expression (S12)
is used to determine the likelihood of a given measured dose. For
the second regression-calibration method Supporting Information
expression (SS12) is used to determine the likelihood of the given
activity measurements. The measured activity is associated with a
multiplicative classical error model, which is determined by the
characteristics of the measuring instrument [55,56]. The dosim-
etry estimation system has a stochastic design to model shared
errors, and to account for uncertain dose-related parameters.
Using that system, certain members of the study team (IAL, VMS)
produced 1000 simulations of the posterior distribution of dose to
the thyroid for all study subjects. The profile likelihood was then
derived by integrating the likelihood over these 1000 dose
simulations. The two regression calibration methods are similar,
but the second makes slightly stronger assumptions on the
independence of certain dosimetric quantities, and a priori may
be regarded as the less plausible model; however, as noted in
Appendix S1, there is little evidence of correlation between thyroid
activity and mass of the sort that would invalidate the use of the
second model. We judge that it is important to assess the effects of
adjusting for dose error using a variety of assumptions and models
to determine the sensitivity of results to these assumptions. The
geometric standard deviation (GSD) was estimated from individual
assessments of measured activity. The models of dose error
generate models for the distribution of thyroid dose or activity in
these intervals, as detailed in Appendix S1. The results of fitting
these models to the dose and activity data for the current (TD-10)
dose data via maximum likelihood methods [21] are given in
Tables S1 and S2.
Thyroid cancer risk model
The primary statistical model used was a logistic model of the
odds ratio (OR), in which the probability of subject i with age at
screening a, gender s, age at exposure e at the time of the accident
(1986) and with true thyroid dose:
Dtri ~fiQ
tr
i =M
tr
i ð1Þ
(Qtri is the true thyroid
131I activity in kBq, Mtri is the true thyroid
mass in g, fi is a scaling constant) being a case of thyroid cancer is
given by:
exp b0zbs1sex~malez
PN
k~1
bk1ak{1ƒavak
 
1zaD exp
cDzk½e{8zt½a{22
zy½a{e{14zg1sex~male
  
1z exp b0zbs1sex~malez
PN
k~1
bk1ak{1ƒavak
 
1zaD exp
cDzk½e{8zt½a{22
zy½a{e{14zg1sex~male
   ð2Þ
[The age at exposure, e, and age at screening, a, were
approximately centered by subtracting off their approximate
mean values in the data, namely 8 and 22 years, respectively; this
facilitated convergence of the iteratively-reweighted least squares
algorithm used to maximize the likelihood [21].] In general only
one of the age or temporal adjustment parameters, k, t or y was
free to vary. As outlined in Appendix S1, we corrected for the
effect of errors in estimates of thyroid activity and mass using two
distinct regression calibration approaches and MCML. Using the
first regression calibration method, adapted from Kukush et al.
[13], lead us to substitute Dtri by E½Dtri jDmesi  using Supporting
Information expression (S16), whereas in the second regression
calibration method we substituted Dtri by E½Dtri jQmesi ,Mmesi  using
Supporting Information expression (SS16); these estimates of dose
were then substituted in expression (2). All parameters were
estimated via maximum likelihood [21]. Appendix S1 also
contains further details of the MCML adjustment methods.
Results
Comparison of doses
We found generally good agreement between the TD-02 doses
used by Tronko et al. [3] and the new (TD-10) dose estimates,
although there was considerable scatter (Figures S1, S2). Figure S3
demonstrates that the dose is distributed very-nearly log-normally.
The details of the distribution of the GSD associated with errors in
the assessments of thyroid activity and mass are given in Table 1;
they are shown as a function of TD-10 dose in Figures 1–3. The
thyroid activity GSD cover a wide range,
exp½sQ,i~1:11{10:03 , although apart from a wide scatter at
(2)
Table 1. Distribution of the geometric standard deviation
(GSD) of errors associated with measurements of thyroid
activity and of thyroid mass across individuals within the
cohort.
TD-10 dose
range (Gy) Range Mean Median 10%, 90%
Thyroid activity GSD ( exp½sQ,i )
0–0.5 1.11–10.13 1.39 1.29 1.16, 1.56
.0.5–1.0 1.12–1.57 1.23 1.22 1.13, 1.33
.1.0–5.0 1.12–2.37 1.23 1.22 1.13, 1.31
.5.0–10.0 1.12–1.40 1.23 1.25 1.13, 1.29
.10.0 1.13–1.47 1.21 1.19 1.17, 1.26
Total 1.11–10.13 1.35 1.26 1.16, 1.49
Thyroid mass GSD ( exp½sM,i )
0–0.5 1.28–1.41 1.39 1.40 1.34, 1.40
.0.5–1.0 1.28–1.41 1.39 1.40 1.33, 1.40
.1.0–5.0 1.28–1.41 1.38 1.40 1.33, 1.40
.5.0–10.0 1.28–1.41 1.39 1.40 1.33, 1.41
.10.0 1.28–1.41 1.38 1.39 1.34, 1.41
Total 1.28–1.41 1.39 1.40 1.34, 1.40
doi:10.1371/journal.pone.0085723.t001
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lower dose (,0.5 Gy), they are mostly under 1.5, with a mean
exp½sQ,i~1:35. The variation in thyroid mass GSD is generally
even less than this (Figure 3), with a range of
exp½sM,i~1:28{1:41 and a mean of exp½sM,i~1:39
(Table 1).
Model fitting
Comparison of effects of various adjustments for dose
error in logistic model. Table 2 demonstrates that using the
logistic model (2), there is a highly statistically significant increasing
dose response (p,0.001) for all four sets of dose estimates and
models (TD02, unadjusted current (TD-10), current (TD-10) +
first/second type of regression-calibration adjustments and
MCML). The dose response using the first regression calibration
method, adapted from Kukush et al. [13], is shown in Figure 4, as
also the unadjusted dose response for comparison. Table 2
demonstrates that without adjustment for dose errors the EOR
was about 2% higher with the TD-10 doses, 5.38 Gy21 (95% CI
1.86, 21.01), than with the TD-02 doses, 5.25 Gy21 (95% CI 1.70,
27.45). The first regression-calibration method, adapted from
Kukush et al. [13], yielded estimates of the EOR of 5.78 Gy21
(95% CI 1.92, 27.04), about 7% higher than estimates unadjusted
for dose error. The second regression-calibration method yielded
an EOR of 4.78 Gy21 (95% CI 1.64, 19.69), about 11% lower
than TD10 estimates unadjusted for dose error. The MCML
method yielded an EOR of 4.93 Gy21 (95% CI 1.67, 19.90),
about 8% lower than the unadjusted TD10 dose estimates.
Table 2 demonstrates that there were borderline significant
indications of downward curvature in the dose response (e.g.,
p=0.112 for curvature assessed using the first set of regression-
calibration-adjusted doses). The effect of allowing for this was to
nearly double the linear coefficient, from 5.78 Gy21 (95% CI 1.92,
27.04), to 9.72 Gy21 (95% CI 2.67, 94.31). However, the effect of
adjustment for dose error on the coefficients of the indicated
linear-exponential model were not much more substantial than for
the linear model. For example the linear coefficient of a linear-
exponential model without dose-error adjustment was 8.85 Gy21
(95% CI 2.60, 54.58), and after adjustment using the first
regression calibration method, adapted from Kukush et al. [13],
this became 9.72 Gy21 (95% CI 2.67, 94.31), an increase of 10%;
after adjustment using the second regression calibration method
this became 8.19 Gy21 (95% CI 2.33, 60.87), a decrease of 7%.
Table 3 demonstrates that the modifying effects of gender, age
at the time of the accident, age at screening and time since the
accident as modifiers of the radiation dose response were generally
not statistically significant (p.0.1) (see also Figure 5); this is the
case whichever set of dose estimates are employed (results not
shown). Table S3 reports the results of sensitivity analyses, in
Figure 1. Distribution of the geometric standard deviation
(GSD) of errors associated with assessments of thyroid activity
GSD as a function of TD-10 thyroid dose. Full dose range.
doi:10.1371/journal.pone.0085723.g001
Figure 2. Distribution of the geometric standard deviation
(GSD) of errors associated with assessments of thyroid activity
GSD as a function of TD-10 thyroid dose. Low dose range.
doi:10.1371/journal.pone.0085723.g002
Figure 3. Distribution of the geometric standard deviation
(GSD) of errors associated with assessments of thyroid mass
GSD as a function of TD-10 thyroid dose.
doi:10.1371/journal.pone.0085723.g003
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which certain variables were added to the background model, and
does not suggest that any improved the fit over age and sex (p$
0.1), nor was there generally any effect on EOR.
Discussion
Re-analysis of the latest follow-up of the Ukrainian-US thyroid
prevalence screening study, and using the most current (TD-10) set
of dose estimates, demonstrates that there is a highly statistically
significant increasing dose response (p,0.001), confirming the
Table 2. Analysis of curvature in fits of EOR model (2) with or without adjustment for dose errors using regression calibration, for
TD-10 doses.
Dose
Dose-response
model p-valuea
Linear ERR (a)
(Gy21) (+95% CI)
Exponential ERR (c)
(Gy21) (+95% CI)
Tronko et al.
(TD-02) dose
aD ,0.001b 5.25
(1.70, 27.45)
Tronko et al.
(TD-02) dose
aD
exp[cD]
0.084 9.13
(2.46, 111.1)
20.09
(20.23, 0.01)
TD-10 unadjusted
dose
aD ,0.001b 5.38
(1.86, 21.01)
TD-10 unadjusted
dose
aD
exp[cD]
0.104 8.85
(2.60, 54.58)
20.11
(20.29, 0.02)
1st regression calibration method
(Kukush et al.) adjusted dose
aD ,0.001b 5.78
(1.92, 27.04)
1st regression calibration method
(Kukush et al.) adjusted dose
aD
exp[cD]
0.112 9.72
(2.67, 94.31)
20.10
(20.28, 0.02)
2nd regression-calibration
method adjusted dose
aD ,0.001b 4.78
(1.64, 19.69)
2nd regression-calibration
method adjusted dose
aD
exp[cD]
0.101 8.19
(2.33, 60.87)
20.09
(20.25, 0.02)
Monte Carlo maximum
likelihood
aD ,0.001b 4.93
(1.67, 19.90)
aD
exp[cD]
0.102 7.97
(2.32, 49.81)
20.09
(20.26, 0.01)
All models have underlying rates adjusted for age (treated categorically) and gender. Unless otherwise stated all CI are profile-likelihood based.
aunless otherwise stated all p-values refer to the improvement in fit of the current row in the Table with that of the model fitted in the row immediately above.
bp-value of improvement in fit compared with a model with no dose terms.
doi:10.1371/journal.pone.0085723.t002
Figure 4. Dose response (+95 CI) for thyroid cancer in relation to TD-10 unadjusted dose, and regression-calibration-adjusted dose
(using 1st method, adapted from Kukush et al. [13]). The models are adjusted for age (treated categorically) and gender in the baseline. Dashed
red line shows odds ratio = 1.
doi:10.1371/journal.pone.0085723.g004
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results of an earlier analysis of this dataset [3]. Adjustment of the
regression for dose errors yielded little change in radiation risk
estimates, as also did the change from the older (TD-02) to the
newer (TD-10) dosimetry.
A major source of uncertainty in estimates of low dose cancer
risk concerns the extrapolation of risks at high dose and high dose-
rates to those at low doses and low dose-rates. Crucial to the
resolution of this area of uncertainty is the flexible modeling of the
dose-response relationship and the importance of both systematic
and random dosimetric errors. The problem of allowing for errors
in dose assessments when estimating dose-response relationships
has recently been the subject of much interest in epidemiology [9].
It is well recognized that measurement error can alter substantially
the shape of this relationship [22]. Much work has been carried
out on assessing the impact of dosimetric error for Japanese atomic
bomb survivor data. In particular, Pierce et al. [23,24] carried out
a dose adjustment prior to the model fitting, allowing for random
dosimetric errors. A similar procedure was followed by Little et al.
[25–28]. This dose adjustment entails the substitution of the
‘‘estimated dose’’ by the expectation of the ‘‘true dose’’ given the
estimated one. This approach to measurement error correction is
an example of regression calibration, which as emphasized by
Carroll et al. [9], is an approximate method in non-linear dose-
effect relationships. It leads to reasonable adjusted point estimates
of the model parameters but does not fully take account of all the
variability induced by the measurement errors.
A Bayesian approach to the measurement-error problem has
been developed [29–31] which rests on the formulation of
conditional independence relationships between different model
components, following the general structure outlined by Clayton
[32]. In this approach three basic sub-models are distinguished
and linked: the disease model, the measurement model and the
exposure model. The general advantage of Bayesian methods, and
other techniques based on use of the full likelihood such as Monte-
Carlo Maximum Likelihood (MCML) [14] is that they take full
account of the impact of dose errors on regression estimates. An
adapted Bayesian method of correction for measurement error –
the two-stage Bayesian method – has been applied to the fitting of
generalized relative risk models to the Japanese atomic bomb
survivor cancer mortality data [10,33–35].
Bayesian methods offer ways of taking account both of
dosimetric uncertainties and modeling ones, for example in the
form and shape of the dose response and in temporal and age
Table 3. Results of fits of optimal excess relative risk model (2) (maximum likelihood fits and 95% profile CI), all based on TD-10
dose estimates adjusted using 1st regression calibration method (of Kukush et al.). All models have underlying rates adjusted for
age (treated categorically) and gender. Parameters are given (with 95% CI), with associated p-values.a Unless otherwise stated all CI
are profile-likelihood based.
Modelnumber Form ofexcess oddsratio model Parameters Estimates(+95% CI)and p-values p-value
1 aD a (Gy21) 5.78(1.92,27.04) ,0.001b
2 aDexp[cD] a (Gy21) 9.72(2.67,94.31) 0.112
c (Gy21) 20.10(20.28,0.02)
3 aDexp[cD +k(e –8)] a (Gy21) 12.54(3.33,73.93) 0.161
c (Gy21) 20.11(20.28,0.01)
k (years21) 20.14(20.37,0.06)
4 aDexp[cD +t(a –22)] a (Gy21) 11.46(3.17,62.58) 0.172c
c (Gy21) 20.11(20.28,0.01)
t (years21) 20.14(20.37,0.06)
5 aDexp[cD +y(a – e –14)] a (Gy21) 10.09(2.58,134.60) 0.874c
c (Gy21) 20.10(20.28,0.02)
y (years21) 0.04(20.51,0.59)
6 aDexp[cD +g1sex =male]d a (Gy21) 40.44(2119.7e,200.6e) 0.171c d
c (Gy21) 20.12(20.30,0.01)
g (years21) 22.21(26.47e,2.05e)
aUnless otherwise stated all p-values refer to improvement in fit of model immediately above indicated one in the Table.
bp-value for improvement in fit over null model (without linear dose term).
cp-value for improvement in fit over model 2, linear-exponential in dose.
dindications of lack of convergence.
eWald-based CI.
doi:10.1371/journal.pone.0085723.t003
Figure 5. Variation of excess relative risk with age at the time
of the accident (using 1st regression calibration method,
adapted from Kukush et al. [13]). Other details as for Figure 4.
doi:10.1371/journal.pone.0085723.g005
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trends. Bayesian Markov Chain Monte Carlo (MCMC) techniques
have previously been much used to assess uncertainties in
radiation risk [10,33–35]. Bayesian MCMC approaches have the
particular advantage that one has an arbitrarily large collection of
realizations of model parameters sampled from the posterior
distribution, so that uncertainty in any function of these
parameters, for example various measures of lifetime population
risk, can be directly evaluated by applying the function to the
posterior chain sample [10,33–35]. More limited assessment of
modeling uncertainties can also be dealt with using multi-model
inference (MMI) [36,37]. MMI methods have also been used in
radiation epidemiology [38–40]. Although not explicitly Bayesian,
MMI is somewhat related to Bayesian model-averaging and
related Bayesian techniques [41]; these Bayesian methods have the
advantage of assessing the parameter uncertainty distribution
more thoroughly than MMI, albeit at somewhat greater compu-
tational cost. However, in general Bayesian MCMC and other
full-likelihood methods such as MCML, employed here, offer a
more flexible and powerful framework for assessing dosimetric and
modeling uncertainty than MMI.
In the present case dose errors were modest, particularly at the
higher doses that will largely drive the trends with dose (Table 1,
Figures 1–3), so that regression calibration methods are likely to be
adequate [9], as confirmed by the results obtained using MCML –
the results of this latter method is close to those obtained using
either of the regression calibration methods, particularly the
second. The two regression-calibration methods we used for
adjusting for dose errors are similar, but the second makes slightly
stronger assumptions on the independence of certain dosimetric
quantities, and a priori may be regarded as the less plausible model;
however, as noted in Appendix S1, there is little evidence of
correlation between thyroid activity and mass of the sort that
would invalidate the use of the second model. Unusually, both
methods take account of mixed Berkson and classical errors in
dose, arising from the distinct measurement and estimation
associated with thyroid mass and 131I thyroid activity measure-
ments. However, neither method makes appreciable difference to
regression risk estimates, the first method leading to a 8% increase
in EOR, the second an 11% decrease, while the MCML method
results in a 8% decrease in EOR, changes which are clearly
minimal in relation to the substantial uncertainties (Table 2). The
reasons for the relatively modest impact of adjusting for dose error
are very largely a consequence of the fact that the errors relating to
the thyroid mass, are Berksonian, and as such would not be
expected to modify risk estimates [9,42], but that in any case both
these and the classical errors associated with measurements of
thyroid activity are relatively small (Table 1, Figures 1–3). Besides
the presence of Berkson measurement error, another possible
reason for the slightly different adjustments to the unadjusted risks
between the two regression-calibration methods is that within the
first such method, there is no assumption about independency of
true activity, Qtri , and measured thyroid gland mass, M
mes
i ,
whereas the other method relies on this assumption.
While it is generally to be expected that correction for the effects
of measurement error, particularly classical error, will be to
increase risks, this is not necessarily the case when, as here, errors
are modest (Table 1, Figures 1–3) and part of the error is of
Berkson type. In particular Schafer et al. [11] document a 8–13%
reduction in risks after adjustment for dose measurement errors in
a study of thyroid cancer in a group of Israeli children treated for
tinea capitis; the errors in this study were largely Berkson. In a
study of effects of air-pollution on lung function in a group of
Southern California children, adjusting for errors in position
(which were largely classical) led to a reduction of effect [43]. More
generally, it is known that non-differential misclassification of
exposure can bias risks away from the null, or induce a change in
sign of a regression trend [44].
The prevalence excess odds ratio that we derived of 5.78 Gy21
(95% CI 1.92, 27.04) using the first regression-calibration method
(Table 2) is somewhat higher than, but statistically consistent with
that which can be derived from the Japanese atomic bomb
survivors exposed to external radiation under the age of 20, 3.07
Gy21 (90% CI 2.14, 4.14) [35]. It is lower than (and again
statistically compatible with) the estimate of 7.7 Gy21 (95% CI 2.1,
28.7) derived from a pooled analysis of five childhood-exposed
groups [45]. However, the analyses of UNSCEAR [35] and Ron
et al. [45] are based on incidence data, and the interpretation is
therefore somewhat different from the prevalence risk that we
estimate. Ron et al. [45] also computed a pooled ERR/Gy
allowing for a non-zero ERR at zero dose (essentially allowing for
an additional offset in risk independent of radiation dose), which
was 3.8 Gy21 (95% CI 1.4, 10.7) [45].
An additional consideration in comparing risks derived here
with low-dose risk coefficients assessed elsewhere is the substantial
uncertainty in the shape of the dose response (in this cohort and
others), and the implied uncertainties this introduces into the
extrapolated low-dose risk. As was previously found using the older
(TD-02) dosimetry [3], we observed borderline significant
downward curvature (in other words, a progressive reduction
with increasing dose in the upward slope of ERR, rather than
negative slope) in the dose response (p=0.101–0.112, Table 2), as
shown in Figure 4. The effect of allowing for this was to nearly
double the low-dose linear coefficient, from 5.78 Gy21 (95% CI
1.92, 27.04), to 9.72 Gy21 (95% CI 2.67, 94.31) (Table 2). The
thyroid is known to be one of the most radiosensitive organs [35],
in particular there is abundant literature documenting excess
thyroid cancer after exposure to external radiation in childhood
[45]. The pooled analysis of Ron et al. [45] indicated that in
general thyroid cancer exhibited a linear dose response, with
indications of a reduction of risk at high doses (.20 Gy). However,
Zablotska et al. observed a similar reduction to ours in risk above 5
Gy in a cohort of Chernobyl-exposed children and adolescents in
Belarus [4]. Cardis et al. also observed a turnover in dose response
above about 5 Gy in a case-control study of Chernobyl-exposed
children in Belarus and the Russian Federation [7]. Sigurdson
et al. [46] observed a reduction in the thyroid cancer dose
response, although at a much higher dose, of about 20 Gy, in a
group followed after treatment with radiotherapy for cancer in
childhood. As such, the turnover that we, Zablotska et al. [4] and
Cardis et al. [7] observe, is reasonably quantitatively consistent. It
is possible that this downturn reflects the effect of cell sterilization,
a well-known phenomenon in radiobiology and radio-epidemiol-
ogy [47], and which has been modelled in various other endpoints
[48-50]. The magnitude of the exponential coefficient, c, that we
obtain is between 20.11 Gy21 and 20.09 Gy21 (Table 2).
Deschavanne and Fertil [51] surveyed 42 in vitro studies that
assessed c for a variety of fibroblastic and other human cell lines,
with values ranging from 21.72 Gy21 to 20.30 Gy21, and a
median value of 20.65 Gy21. As such, our value looks a little too
small (too near 0). However, there may be compensating tissue
repopulation during the course of exposure to 131I from
Chernobyl, which would be expected to substantially reduce the
observed value of c [52].
There were no strong indications (p.0.1) of variation of relative
risk with age at exposure, age at screening, or time since exposure
(Table 3). There is considerable evidence that thyroid cancer
relative risk decreases with increasing age at exposure [35,45]; it is
not altogether obvious why this was observed only relatively
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weakly here (Figure 5). There are weaker indications of eventual
reductions of thyroid cancer relative risk with increasing time after
exposure among those exposed in childhood [45,53,54]. It is likely
that our cohort, with follow-up confined to a relatively narrow
time interval, 1998–2000, about 12–14 years after the Chernobyl
accident, lacks the power to detect such downturns in risk, which
in any case would not be expected until 15–19 years after the
accident [45].
Conclusions
The results of the paper are based on a screening study of the
most heavily exposed populations in Ukraine who were aged
under 18 years old at the time of the Chernobyl accident. The
paper extends previous analyses by using revised thyroid cancer
dose estimates. This paper addresses for the first time the errors
that are present in absorbed thyroid doses, and their effect on
thyroid cancer risk estimates; however, the effects of adjusting for
dose error are minimal, resulting in changes to cancer risk
estimates by between 211% and +7%. In relation to the other
uncertainties in the data, these relatively modest changes in risk
resulting from taking dose errors into account are largely a
consequence of the modest size of the errors and the fact that a
component (associated with measurement of thyroid mass) is of
Berkson type. There is borderline statistically significant reduction
in the upward slope of thyroid cancer risk at high doses.
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